{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"30.780","rs_stock_flag":false,"fiscal_year_end":"2025年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"73,598,888","primaryexch":"香港交易所","ric":"3880.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BR0ZLP5","am":"6.46","iv":"","ew_strike":"","as":"30.800","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"30.600","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"28.100","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"徐琪","underlying_ric":"3880.HK","hi52":"41.720","issuer_name":"泰德醫藥(浙江)股份有限公司 - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"29.380","mkt_cap":"2.25","f_aum_hkd":null,"ew_sub_per_to":"","ls":"30.600","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.060","aum":"","issued_shares_class_B":null,"vo":"215.70","secondary_listing_flag":false,"listing_date":"2025年6月30日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"泰德醫藥(浙江)股份有限公司 - H股","nm_s":"泰德醫藥","sym":"3880","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"泰德醫藥（浙江）股份有限公司是一家主要從事多肽的合約研究、開發和生産的中國公司。該公司主要提供合約研究機構（CRO）服務，即多肽新化學實體（NCE）發現合成、合約開發及生産機構（CDMO）服務即多肽化學、制造及控制（CMC）開發以及商業化生産。該公司的服務主要專注于向客戶提供活性藥物成分（APIs），而非藥品。該公司也爲客戶提供多肽類藥物開發、生産、CMC申報支持服務。該公司主要在國內市場和海外市場開展業務。","op":"30.680","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國浙江省杭州市<br/>錢塘區下沙街道<br/>銀海科創中心<br/>6幢501-11室","pc":"-0.20","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"30.660","isin":"CNE100006S86","moneyness":""}},"qid":"1759074429760"}
